Employment

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Retrieved on: 
Tuesday, April 9, 2024
Quality of life, Senior, Eye, Employment, Compensated emancipation, Diabetic retinopathy

BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu.

Key Points: 
  • BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu.
  • The awards were approved by the Compensation Committee of Ocular and were made as inducements material to Dr. Zhu’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock unit award is scheduled to vest over three years, in equal annual installments, beginning on Dr. Zhu’s employment commencement date and subject to her continued service to Ocular through the applicable vesting dates.
  • The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

Greater Sacramento Region Recognized as a National Leader in Equitable Economic Growth by Brookings 2024 Metro Monitor Report

Retrieved on: 
Tuesday, April 9, 2024
Employment, Growth, MSA, California State University, UC, BHC, Entrepreneurship, Poverty, Student, GMP, Samsung, Renewable energy

Sacramento, CA, April 09, 2024 (GLOBE NEWSWIRE) -- The 2024 Brookings Metro Rankings , analyzing 10-year economic performance of the country’s 54 largest metros through five key indicators – growth, prosperity, overall inclusion, racial inclusion and geographic inclusion – highlight the Greater Sacramento region's remarkable economic advancements.

Key Points: 
  • Sacramento, CA, April 09, 2024 (GLOBE NEWSWIRE) -- The 2024 Brookings Metro Rankings , analyzing 10-year economic performance of the country’s 54 largest metros through five key indicators – growth, prosperity, overall inclusion, racial inclusion and geographic inclusion – highlight the Greater Sacramento region's remarkable economic advancements.
  • Notably, the region now boasts the second highest decrease in relative poverty rate in the country (-5%), a testament to the region's improvements in economic equity.
  • Our region stands as a shining exemplar of accessibility and opportunity for everyone and will only continue to lead by example.”
    The Greater Sacramento region is undergoing unprecedented economic momentum.
  • For more information, access the Brookings Metro Monitor Report: https://www.brookings.edu/articles/metro-monitor-2024/

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in HireRight Holdings Corporation of Class Action Lawsuit and Upcoming Deadlines – HRT

Retrieved on: 
Monday, April 8, 2024
Employment, Prior, Organization, Risk management, Hold, HireRight, Form, Risk, District court, Defendant, News, Ext, LLP, IPO, Alpha, Prospectus, Complaint, Publication, HRT, Pomerantz, Action Replay, Court, Register, Security (finance)

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) and certain officers.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against HireRight Holdings Corporation (“HireRight” or the “Company”) (NYSE: HRT) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages HireRight Holdings Corporation Investors to Secure Counsel in Securities Class Action – HRT

Retrieved on: 
Monday, April 8, 2024
Titan, Employment, HireRight, Risk, IPO, Prospectus, HRT, Advertising, Court

WHAT TO DO NEXT: To join the HireRight class action, go to https://rosenlegal.com/submit-form/?case_id=23874 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the HireRight class action, go to https://rosenlegal.com/submit-form/?case_id=23874 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Retrieved on: 
Monday, April 8, 2024
MSD, Employment, Fordham University, Biotechnology, CFO, Patient, Research, Merck, Gruntal & Co., Acquisition, IPO, MBA, Initial, Therapy, HSBC, Gene Mack, Pharmaceutical industry

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.

Key Points: 
  • BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
  • “We are thrilled to welcome Gene as our new CFO,” commented Gain CEO Matthias Alder.
  • Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023.
  • “I am excited to join Gain Therapeutics during this important stage of corporate growth and scientific progression.

Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against HireRight Holdings Corporation (HRT)

Retrieved on: 
Saturday, April 6, 2024
Employment, IRS, HireRight, Risk, District court, Lead, CFTC, LLP, COPY, IPO, Prospectus, Complaint, Fraud, HRT, Medicare, Person, Security (finance)

RADNOR, Pa., April 06, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee against HireRight Holdings Corporation (“HireRight”) ( NYSE: HRT ).

Key Points: 
  • RADNOR, Pa., April 06, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Tennessee against HireRight Holdings Corporation (“HireRight”) ( NYSE: HRT ).
  • The action charges HireRight with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • Kessler Topaz Meltzer & Check, LLP encourages HireRight investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against HireRight, Deutsch v. HireRight Holdings Corporation, et al., Case No.

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, April 5, 2024
Therapy, Employment

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Company’s compensation committee granted nonstatutory stock options to purchase up to an aggregate of 80,000 shares of the Company’s common stock to the new employees on April 2, 2024, at an exercise price of $6.93 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on April 2, 2024.
  • The options have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee’s start date and 2.0833% of the shares underlying the option vesting monthly thereafter, subject to such employee’s continued service to the Company through the applicable vesting dates.

Stitch Fix Announces New Employee Inducement Grant

Retrieved on: 
Friday, April 5, 2024
Stitch Fix, SAN, Employment, RSU

SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ:SFIX), the leading online personal styling service, today announced that effective April 2, 2024, the compensation committee of the company’s board of directors granted Lillian Reaume, Chief People Officer, restricted stock units (RSUs) to acquire 509,091 shares of the company’s Class A common stock.

Key Points: 
  • SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ:SFIX), the leading online personal styling service, today announced that effective April 2, 2024, the compensation committee of the company’s board of directors granted Lillian Reaume, Chief People Officer, restricted stock units (RSUs) to acquire 509,091 shares of the company’s Class A common stock.
  • One fourth (25%) of the RSUs will vest on September 11, 2024.
  • The RSUs were granted pursuant to, and are subject to the terms of, the Stitch Fix, Inc.
  • Amended and Restated 2019 Inducement Plan and forms of RSU agreements thereunder, which were approved by the company's board of directors in April 2022 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

FeedbackHR.com - The Quantum Leap in Employee Feedback Analysis

Retrieved on: 
Friday, April 5, 2024
Workforce, Trust, Morale, Glassdoor, HR, Pulse, Employment, Acquisition, Human

FeedbackHR.com emerges as a revolutionary platform, tailored for company executives, HR professionals, and hiring managers aiming to tune into the insights of their workforce effectively.

Key Points: 
  • FeedbackHR.com emerges as a revolutionary platform, tailored for company executives, HR professionals, and hiring managers aiming to tune into the insights of their workforce effectively.
  • Offering more than your average feedback tool, FeedbackHR.com provides an intelligent, intuitive employee feedback platform that caters to the intricate needs of various industries and roles.
  • Through customizable templates and real-time feedback tracking, companies are empowered to keep a pulse on employee morale swiftly.
  • By identifying the emotional states of employees, the platform redirects the feedback into constructive or celebratory paths accordingly – an innovation that quells the dissemination of negative public reviews.

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Retrieved on: 
Friday, April 5, 2024
External, Medical biology, IO, Employment, Survival, Pfizer, Business development, Cancer, Engineering, Doctor of Philosophy, Eli Lilly and Company, Kadmon Corporation, Vaccine, Lead, Pharmaceutical industry

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.

Key Points: 
  • NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.
  • Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships.
  • Dr. Miyara will be based in the United States, report to IO Biotech’s CEO, Mai-Britt Zocca, Ph.D., and be a member of the company’s executive team, effective immediately.
  • “We are very excited to welcome Faiçal to IO Biotech,” said Dr. Zocca.